• Explore /
  • Poster
  • / Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.

Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.

Abstract Poster

Authors

Robert Burger

Robert Allen Burger

Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA

Robert Allen Burger , Danielle Enserro , Krishnansu Sujata Tewari , Mark F. Brady , Michael A. Bookman , Gini F. Fleming , Helen Q Huang , Howard D. Homesley , Jeffrey Fowler , Matthew Boente , Leslie M. Randall , John K. Chan , James Stuart Ferris , Philip J. DiSaia , Larry J. Copeland , Robert S. Mannel , Michael J. Birrer , Bradley J. Monk

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT00262847

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5517)

DOI

10.1200/JCO.2018.36.15_suppl.5517

Abstract #

5517

Poster Bd #

244

Abstract Disclosures

Similar Posters

First Author: Kristina Lindemann

First Author: Florian Heitz

First Author: Benoit You

First Author: Elena Ioana Braicu